Itovebi, Ibrance, and Faslodex significantly improved OS in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer compared to placebo. The INAVO120 trial showed a median OS of 34.0 months ...

The U.S. Food and Drug Administration (FDA) has granted priority review and breakthrough therapy designation to the ...

The evERA study showed significant PFS improvements with giredestrant plus everolimus in ER-positive, HER2-negative breast ...

In HR+/HER- early breast cancer, the DFS benefits of adjuvant ribociclib plus NSAI treatment compared to NSAI alone persisted even a year after treatment completion.

The FDA has approved the combination of lurbinectedin (Zepzelca) and atezolizumab (Tecentriq) as a first-line maintenance treatment for patients with extensive-stage small cell lung cancer (ES-SCLC) ...

Patients receiving ribociclib 400 mg had a shorter QTcF (12.5 vs 19.7 ms at cycle 1 day 15, 2 hours post-dose) and a lower ...

HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Previously Treated with Endocrine Therapy The ...

ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer ...

A total of 263 patients were randomly assigned, among which 254 patients formed the full analysis set. At the median follow-up time of 50.7 months, 203 PFS events occurred. The metronomic capecitabine ...

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with ...